Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

Prostate Cancer companies working in the treatment market are Telix Pharmaceuticals, Merck and Orion, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca, Kangpu Biopharmaceuticals, Merus, Blue ...

FLT3 Inhibitors for Acute Myeloid Leukemia Market to Reach USD 440 Million by 2025, Projected to Grow at 8% CAGR Through 2032 The global FLT3 inhibitors for acute myeloid leukemia market is poised to ...

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...

With a solid cash position and expected profitability by late 2026, Apellis stock is set for recovery. Read the latest ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Complete Astellas Pharma Inc. ADR stock information by Barron's. View real-time ALPMY stock price and news, along with industry-best analysis.

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...